← Scroll for more →
Kyntra Bio, Inc. (KYNB)
Pharmaceutical Preparations
Latest Price
$4.65
TTM P/E
0.10
Normalized P/E
0.55
TTM Div Yield
--
Fwd Div Yield
--
Book Value
0.28
P/B Ratio
16.57
Valuation metrics
adjust assumptions →EPS: $45.37
Target P/E: 1×
Formula: EPS × P/E
P/E Fair Value
$45.37
+893% upside
Institutional Ownership
21.9% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 400.0K | $3.0M | 9.88% | -- | 2026-06-30 |
| Vanguard Capital Management LLC | 159.9K | $1.0M | 3.95% | +3.3K | 2026-06-30 |
| BlackRock, Inc. | 84.3K | -- | 2.08% | -1 | 2026-06-30 |
| Geode Capital Management, LLC | 43.2K | -- | 1.07% | -2.8K | 2026-06-30 |
| HighTower Advisors, LLC | 39.7K | -- | 0.98% | +2 | 2026-06-30 |
| Two Sigma Investments, LP | 39.5K | -- | 0.98% | -- | 2026-06-30 |
| Renaissance Technologies LLC | 27.1K | -- | 0.67% | -400 | 2026-06-30 |
| Vanguard Fiduciary Trust Co | 24.1K | -- | 0.60% | +163 | 2026-06-30 |
| Birchview Capital, LP | 22.6K | -- | 0.56% | -- | 2026-06-30 |
| State Street Corp | 20.3K | -- | 0.50% | -- | 2026-06-30 |